Abstract:Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. The in vitro activity of two new fluoroquinolones, delafloxacin and finafloxacin, were evaluated against M. hominis and Ureaplasma spp. The MICs of delafloxacin, finafloxacin, and two classical fluoroquinolones (moxifloxacin and levofloxacin) were tested against 29 M. hominis and 67 Ureaplasma spp. isolates using the broth microdilution method. The molecular mechanisms underlying fluoroquinolone resistance were also investigated. Delafloxacin exhibited low MICs against M. hominis and Ureaplasma spp., including the levofloxacin-resistant isolates. For M. hominis, delafloxacin showed low MIC90 value of 1 mu g/mL (MIC range, <0.031 -1 mu g/mL) compared to 8 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 mu g/mL for levofloxacin. For U. parvum and U. urealyticum, delafloxacin had low MIC90 values (U. parvum, 2 mu g/mL; U. urealyticum, 4 mu g/mL) compared to 16 -32 mu g/mL for finafloxacin, 16 mu g/mL for moxifloxacin, and 32 - >32 mu g/mL for levofloxacin. The two mutations GyrA S153L and ParC S91I were commonly identified in fluoroquinolone-resistant M. hominis, and ParC S83L was the most frequent mutation identified in fluoroquinolone-resistant Ureaplasma spp. Delafloxacin displayed lower MICs against fluoroquinolone-resistant isolates of both M. hominis and Ureaplasma spp. that have mutations in the quinolone resistance determining regions (QRDRs) than the two classical fluoroquinolones. Delafloxacin is a promising fluoroquinolone with low MICs against fluoroquinolone-resistant M. hominis and Ureaplasma spp. Our study confirms the potential clinical use of delafloxacin in treating antimicrobial-resistant M. hominis and Ureaplasma spp. infections. IMPORTANCE Fluoroquinolone resistance in Mycoplasma hominis and Ureaplasma spp. is on the rise globally, which has compromised the efficacy of the currently available antimicrobial agents. This study evaluated the antimicrobial activity of two new fluoroquinolones, delafloxacin and finafloxacin, for the first time, against M. hominis and Ureaplasma spp. clinical isolates. Delafloxacin and finafloxacin displayed different antimicrobial susceptibility profiles against M. hominis and Ureaplasma spp. in vitro. Delafloxacin was found to be more effective against M. hominis and Ureaplasma spp. than three classical fluoroquinolones (finafloxacin, moxifloxacin, and levofloxacin). Finafloxacin displayed activity similar to moxifloxacin but superior to levofloxacin against M. hominis and Ureaplasma spp. Our findings demonstrate that delafloxacin is a promising fluoroquinolone with outstanding activity against fluoroquinolone-resistant M. hominis and Ureaplasma spp.

The Serum Bactericidal Activity of Gatifloxacin

Bacteriological Efficacy of Gatifloxacin Methanesulfonate Tablet on Acute Bacterial Infections

A Double-Blind, Randomized Controlled Clinical Study:Gatifloxacin Vs Levofloxacin in Treatment of 98 Patients with Urinary Tract Infections

A Randomized Controlled Clinical Study on a New Quinolone,gatifloxacin, in the Treatment of Respiratory Tract Infections

Clinical randomized controlled trials of Gatifloxacin injection in the treatment of bacterial infections of lower respiratory tract and urinary tract

A randomized comparative study of gatifloxacin and ciprofloxacin in the treatment of bacterial infections

A Multicenter, Single-Blind, Randomized Comparison of Sequential Therapy of Gatifloxacin Versus Levofloxacin in the Treatment of Bacterial Infections

Clinical Randomized Controlled Trials of Gatifloxacin Injection in Treatment of Bacterial Infections of Respiratory Tract

<i>In Vitro</i> Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and <i>Ureaplasma</i> Species

Double-blind Randomized Controlled Clinical Trial on Gatifloxacin Versus Levofloxacin Injection for Treating Acute Bacterial Infections

Pharmacokinetics of Gatifloxacin Tablet in Healthy Volunteers

In vitro activity of gatifloxacin compared with 8 comparators against the Ureaplasma strains isolated from Shanghai, China

In vitro and in vivo activity of tosufloxacin

In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections

Study in Vitro of Antimicrobial Activity of Domestic Sparfloxacin

Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers

The Effects of Gatifloxacin or Ciprofloxacin Combined with Cefmetazole on Escherichia Coli in Vitro

In vitro antibacterial activity study of gemifloxacin mesylate for injection

Randomized Controlled Study on Gatifloxacin and Levofloxacin Injection in the Treatment of Acute Gonococcal Urinary and Reproductive Tract Infections

Pharmacokinetics of gatifloxacin mesylate tablet in healthy volunteers after a single oral administration

Clinical Trial on Gatifloxacin Against Acute Exacerbation of Chronic Bronchitis (AECB) in Adults